4 citations
,
July 2025 in “International Journal of Molecular Sciences” Targeting amphiregulin may improve treatment for fibrosis and cancer.
3 citations
,
March 2017 in “Regulatory toxicology and pharmacology” Aleglitazar and its major metabolite are safe enough to proceed to Phase 3 clinical trials.
November 2011 in “Nature Clinical Practice Urology” 5ARIs effectively treat and manage BPH by reducing prostate size and symptoms.
August 2021 in “Revista Colombiana de Reumatología/Revista Colombiana de Reumatologia” Janus kinase inhibitors may effectively treat severe alopecia areata unresponsive to other treatments.
1 citations
,
September 2022 in “Sudan Journal of Medical Sciences” Danoprevir, remdesivir, and saridegib may effectively inhibit SARS-CoV-2.
March 2023 in “Clinical Toxicology” June 2025 in “Acta Dermato Venereologica” Low-dose Ritlecitinib may help children with stubborn Alopecia Areata.
November 2025 in “Mendeley Data” JAK inhibitors can be safely used for alopecia areata in patients with latent hepatitis B or stable tuberculosis with proper monitoring.
January 2023 in “Journal of clinical pharmacy and therapeutics” Isoliensinine, a natural compound, prevents stress-related hair greying by blocking a specific receptor on hair cells.
January 2011 in “Reactions Weekly”
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib effectively regrows scalp hair in most people with severe alopecia areata.
April 2017 in “The Journal of urology/The journal of urology” SHH protein helps nerve regeneration in hypertensive rats.
2 citations
,
May 2025 in “Journal of Clinical Medicine” Upadacitinib is safe and effective for treating alopecia areata and atopic dermatitis in children.
16 citations
,
April 2014 in “Expert Opinion on Pharmacotherapy” Teriflunomide is an effective and safe first-line oral treatment for relapsing multiple sclerosis.
16 citations
,
December 2011 in “Actas Dermo-Sifiliográficas” Propranolol is effective and safe for treating infantile hemangioma, but more research is needed for dosing and monitoring guidelines.
April 2023 in “Journal of Investigative Dermatology” Two new IRAK4-inhibitors effectively reduced skin inflammation and immune response markers in healthy volunteers.
17 citations
,
August 2002 in “AIDS” Indinavir and ritonavir therapy can cause reversible hair loss.
8 citations
,
October 2022 in “Dermatology practical & conceptual” Tofacitinib and ruxolitinib are effective and safe for treating various autoimmune skin and joint disorders.
July 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively improves hair regrowth and physician satisfaction in severe alopecia areata over time.
10 citations
,
January 2023 in “Acta dermato-venereologica” Baricitinib and deuruxolitinib are effective for treating alopecia areata, but their efficacy depends on the dose.
1 citations
,
June 2024 in “Frontiers in Physiology” Endoplasmic reticulum stress plays a key role in developing atherosclerosis.
2 citations
,
March 2005 in “Cancer biology & therapy” Bexxar treatment led to a high response rate in patients with advanced-stage, treatment-resistant follicular lymphoma.
18 citations
,
February 2024 in “Nutrients” A new pomegranate extract lowers blood pressure and has health benefits.
Integrating ABI screening in clinics can improve patient care for those at risk of peripheral artery disease.
September 2025 in “Asian journal of pediatric dermatology.” Abrocitinib helped a 14-year-old girl with severe alopecia areata regrow her hair significantly.
February 2024 in “Practical Diabetes” Spironolactone helps reduce hospital visits and death from heart issues, lowers blood pressure, but has unclear effects on heart failure with normal heart pump function and can cause high potassium and breast enlargement in men.
May 2018 in “Dermatologic Surgery” 3 citations
,
June 2024 in “Pharmacia” New isatin-gallate hybrids show promise as antioxidants, cancer treatments, and coronavirus inhibitors.
2 citations
,
November 2014 in “The journal of investigative dermatology/Journal of investigative dermatology” Oral tofacitinib can treat both psoriasis and alopecia universalis by normalizing inflammatory pathways.